Results 161 to 170 of about 2,703,409 (308)

MetaPaCS: A Novel Meta‐Learning Framework for Pancreatic Cancer Subtype Identification

Advanced Intelligent Systems, EarlyView.
We have developed MetaPaCS, an ensemble meta‐learning framework for reliable prediction of pancreatic cancer subtypes with high accuracy. MetaPaCS is capable of capturing subtype‐specific distinct gene expression patterns and drug‐disease associations for pancreatic cancer.
Nick B. Peterson, Mengtao Sun, Xinchao Wu, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

Neoadjuvant Therapy for Malignant Melanoma

This thesis explores the emerging role of neoadjuvant therapy in the management of resectable malignant melanoma. Neoadjuvant approaches using immune checkpoint inhibitors and targeted therapies - offer potential benefit such as early immune activation ...
Shoval, Shahaf
core  

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Vine copula knockoffs for variable selection in gene expression studies

Canadian Journal of Statistics, EarlyView.
Abstract Identifying clinical and genetic markers is essential for stratifying cancer patients by survival outcomes and guiding personalized treatment strategies. However, gene expression studies often involve high‐dimensional predictors with mixed data types and complex dependence, which complicates reliable variable selection.
José Ulises Márquez Urbina, Alejandro Román Vásquez, Graciela González Farías, Gabriel Escarela   +3 more
wiley   +1 more source

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai, Anton L V Avanceña, Juan P Cata, Jamie C. Barner, Sharon H. Giordano, Chanhyun Park, Hui Zhao, Kirk E. Evoy, John K. Lin, Jennifer C. Spencer, Mariana Chavez‐MacGregor, Kelly K. Hunt, Kerollos Nashat Wanis   +12 more
wiley   +1 more source

Neoadjuvant Therapy for Non-Small Cell Lung Cancer: Recent Advances and Future Directions. [PDF]

Cancer Med
An H, Zhao J, Chen W, Li Y, Yan Y, Zhou C, Li R, Yao X, Dong X, Yang X, Hu Y, Chen J, Han C, Bai Y, Xu Y, Li Y.   +15 more
europepmc   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Circulating tumor DNA in neoadjuvant therapy for solid tumors. [PDF]

Front Oncol
Huang X, Deng Y, Shen Y.
europepmc   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source